Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC's Consent Orders Chill Speech In Industry, Emord Petition Says

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission's recently adopted requirements for substantiating health claims for dietary supplements have a chilling effect on free speech and violate statutory and constitutional regulations, a petition to the agency says.

You may also be interested in...



Supplement Claim Ruling Rejects FTC View Of “Competent And Reliable” Evidence

In a decision that suggests FTC may have to broaden what it considers competent and reliable evidence, a federal court in Florida rules supplement firm Garden of Life performed adequate due diligence in making claims and was not in contempt of an order for permanent injunction.

Supplement Claim Ruling Rejects FTC View Of “Competent And Reliable” Evidence

In a decision that suggests FTC may have to broaden what it considers competent and reliable evidence, a federal court in Florida rules supplement firm Garden of Life performed adequate due diligence in making claims and was not in contempt of an order for permanent injunction.

Dannon's FTC Settlement Requires FDA Approval For Cold/Flu Immunity Claims

The Dannon Co. will drop "exaggerated" health claims for two yogurt products, including claims in advertising with actress Jamie Lee Curtis, under a settlement with the Federal Trade Commission.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel